Chronic Granulomatous Disease (CGD) Market Analysis and Outlook Report 2026-2036 - Emerging Gene Therapies, Lentiviral Vector-based Therapies and CRISPR-Cas9 Gene Editing, Ignite Hope [Yah...
Rocket Pharmaceuticals, Inc. (RCKT)
Last rocket pharmaceuticals, inc. earnings: 3/5 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
rocketpharma.com
Company Research
Source: Yahoo! Finance
Dublin, April 21, 2026 (GLOBE NEWSWIRE) -- The "Chronic Granulomatous Disease Market: Focus on Treatment Type, Route of Administration, Distribution Channel, Country and Regional Analysis, 2026-2036" has been added to ResearchAndMarkets.com's offering. The Chronic Granulomatous Disease (CGD) market is a small but growing segment within the rare disease and immunology space. Current treatment is centered on long-term prophylactic use of antibiotics and antifungals, supported in some cases by interferon to strengthen immune responses. Hematopoietic stem cell transplantation (HSCT) is the only curative option available today, though it carries risks such as graft rejection and graft-versus-host disease, and it requires access to highly specialized centers. Emerging gene therapies, however, represent a major shift in the treatment landscape, offering the potential to correct the genetic defect at its root and permanently cure the condition. Several major trends are shaping this mar
Show less
Read more
Impact Snapshot
Event Time:
RCKT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RCKT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RCKT alerts
High impacting Rocket Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RCKT
News
- Rocket Pharmaceuticals (RCKT) had its price target raised by Bank of America Corporation from $8.00 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Why Rocket Pharmaceuticals (RCKT) Got a Commercial Boost From FDA Approval of KRESLADI [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals (RCKT) Is Down 8.9% After FDA Accelerated Approval Of KRESLADI Gene Therapy [Yahoo! Finance]Yahoo! Finance
- Rocket Pharmaceuticals: Kresladi Approval Validates Platform, But Commercial Upside Remains Limited [Seeking Alpha]Seeking Alpha
- Rocket Pharmaceuticals (RCKT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $11.00 price target on the stock.MarketBeat
RCKT
Earnings
- 2/26/26 - Beat
RCKT
Sec Filings
- 4/6/26 - Form ARS
- 4/6/26 - Form DEFA14A
- 4/6/26 - Form DEF
- RCKT's page on the SEC website